# Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices

> **NCT02596009** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 97 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive (COPD)

## Interventions

- **DEVICE:** Breezhaler®
- **DEVICE:** Ellipta®
- **DEVICE:** Handihaler®

## Key facts

- **NCT ID:** NCT02596009
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-16
- **Primary completion:** 2016-04-29
- **Final completion:** 2016-04-29
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596009, "Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02596009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*